Belinostat decreases STAT1 and IRF1 expression and significantly enhances the antilymphoma activity of Reolysin. (A) Belinostat treatment decreases STAT1 and IRF1 expression. Parental TCL cells were treated with 5 and 10 μM belinostat for 24 hours. STAT1 and IRF1 expression were determined by immunoblotting. (B-C) Reolysin enhances the activity of belinostat in both parental and belinostat-resistant TCL cells. Cells were treated with 0.25 μM belinostat and 45 or 90 PFUs Reolysin per cell, respectively, for Karpas-299 and HuT-78 and the combination for 72 hours (B) or 48 hours (C). Cell viability was determined by MTT assay and apoptosis was measured by PI-FACS analysis. Data are shown as mean ± SD (n = 3). *P < .05 indicates a significant difference compared with Control or **P < .05 compared with either monotherapy.